Laboratory of Immunology, Regina Elena National Cancer Institute, Rome, Italy.
Lancet Oncol. 2012 May;13(5):e205-11. doi: 10.1016/S1470-2045(12)70003-7.
Gene expression profiling is a powerful method to classify human tumours on the basis of biological aggressiveness, response to therapy, and outcome for the patient, but its application in melanoma lags behind that of other cancers. From more than 100 articles available on the topic, we selected 14 focusing on patients' outcome. We review and briefly discuss salient findings, and list ten reasons why melanoma molecular classes are not yet used in clinical diagnosis and prognosis. The available evidence suggests that we are on the verge of creating a framework for the use of melanoma molecular classes in prognosis, but so far there is little consensus to put together informative diagnostic and prognostic gene sets.
基因表达谱分析是一种强大的方法，可以根据生物侵袭性、对治疗的反应和患者的预后对人类肿瘤进行分类，但在黑色素瘤中的应用落后于其他癌症。在关于该主题的 100 多篇文章中，我们选择了 14 篇重点关注患者预后的文章。我们回顾并简要讨论了突出的发现，并列出了黑色素瘤分子分类尚未用于临床诊断和预后的十个原因。现有证据表明，我们即将创建一个用于黑色素瘤分子分类的预后框架，但到目前为止，还没有达成共识来组合有信息的诊断和预后基因集。
